GSK files for European approval of gene therapy
This article was originally published in Scrip
GlaxoSmithKline has filed for approval to market a gene therapy in Europe. GSK2696273, developed with Italian scientists from Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR), is for the treatment of the ultra-rare disease adenosine deaminase severe combined immunodeficiency syndrome (ADA-SCID) in patients for whom a suitable bone marrow donor cannot be found.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.